公开(公告)号：US20240189387A1

公开(公告)日：2024-06-13

申请号：US18468506

申请日：2023-09-15

申请人： Ensoma, Inc.

发明人： Veit Schmelmer

IPC分类号： A61K38/17 ,  A61K9/00 ,  A61K31/395 ,  A61P35/00

CPC分类号： A61K38/17 ,  A61K9/0019 ,  A61K31/395 ,  A61P35/00

摘要： The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, such as a donor with multiple myeloma, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a patient with multiple myeloma for performing an autologous stem cell transplant to treat the patient's multiple myeloma.

公开(公告)号：US20240301362A1

公开(公告)日：2024-09-12

申请号：US18268393

申请日：2021-12-22

申请人： Ensoma, Inc.

发明人： Soumitra Roy

IPC分类号： C12N7/00 ,  C12N15/86

CPC分类号： C12N7/00 ,  C12N15/86 ,  C12N2710/10021 ,  C12N2710/10343 ,  C12N2710/10344 ,  C12N2710/10352 ,  C12N2800/40

摘要： The present disclosure provides, among other things, Ad35 helper genomes and vectors useful in gene therapy, e.g., for production of helper-dependent Ad35 donor vectors. Helper genomes of the present disclosure include a conditionally defective packaging sequence.

公开(公告)号：US20240108752A1

公开(公告)日：2024-04-04

申请号：US18268392

申请日：2021-12-22

申请人： Ensoma, Inc.

发明人： Soumitra Roy ,  Ashvin Reddy Bashyam

IPC分类号： A61K48/00 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/17 ,  A61K38/46 ,  C12N15/86

CPC分类号： A61K48/0041 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/1774 ,  A61K38/465 ,  C12N15/86 ,  C12N2710/10022 ,  C12N2710/10043 ,  C12N2710/10071

摘要： The present disclosure includes adenoviral vectors characterized by efficient transduction of HSCs, e.g., for in vivo gene therapy. The present disclosure includes, among other things, Ad3, Ad7, Ad11, Ad14, Adpatentdocket@choate.com16, Ad21, Ad34, Ad37, and Ad50 vectors and genomes. Ad3, Ad7, Ad11, Ad14, Ad16, Ad21, Ad34, Ad37, and Ad50 vectors and genomes of the present disclosure can include therapeutic payloads.